Ondansetron B. Braun

Ondansetron, the active ingredient in Ondansetron B. Braun, is a 5-HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery in adult and pediatric patients. GNH USA supplies Ondansetron B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ondansetron B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron B. Braun is a selective 5‑HT3 receptor antagonist that reduces nausea and vomiting triggered by several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: helps control the acute and delayed phases of CINV. - Radiation‑induced nausea and vomiting: reduces the incidence of nausea and vomiting during and after radiation therapy. - Post‑operative nausea and vomiting: decreases the frequency of postoperative PONV in patients undergoing surgery. - Pregnancy‑related vomiting: may be considered for severe hyper‑emesis gravidarum when other measures have failed — but only under strict medical supervision.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement changes. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with high intravenous doses. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

When using Ondansetron B. Braun, clinicians should consider several safety measures.

- Cardiac monitoring: assess baseline ECG in patients with known cardiac risk. - Electrolyte balance: correct hypokalaemia or hypomagnesemia before infusion. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Pediatric dosing: adjust dose according to weight and age guidelines. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Ondansetron may interact with several medication classes.

Major Interactions (Avoid): - QT‑prolonging drugs: concurrent use with other agents that lengthen the QT interval can increase arrhythmia risk. - Apomorphine: may cause profound hypotension and loss of consciousness.

Moderate M​ ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - Serotonergic agents: monitor for signs of serotonin syndrome when combined with SSRIs, SNRIs, or MAO‑inhibitors. - CYP3A4 inhibitors: may increase ondance­trone plasma levels; dose adjustment may be needed. -  CYP ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ -    t